A study in healthy men to test how different doses of BI 3031185 are tolerated and how food influences the amount of BI 3031185 in the blood

2023-507941-28-00 Protocol 1516-0001 Human pharmacology (Phase I) - First administration to humans Ended

Start 8 Mar 2024 · End 28 Aug 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1516-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 76
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Not possible to specify
Trial duration
8 Mar 2024 → 28 Aug 2024
Decision date (initial)
2024-02-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-507941-28-00
WHO UTN
U1111-1297-4672

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

VersionLevelCodeTermSystem organ class
26.0 LLT 10088820 Clinical trial healthy volunteer 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 76 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Boehringer Ingelheim Pharma GmbH & Co. KG
Global Clinical Development & Operations, Birkendorfer Strasse 65, 88397, Biberach An Der Riss

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-03-08 2024-08-28 2024-03-11 2024-07-02

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-28 Germany Acceptable
2024-02-14
2024-02-16